These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 10522720)

  • 1. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
    Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
    Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas.
    Bartsch D; Bastian D; Barth P; Schudy A; Nies C; Kisker O; Wagner HJ; Rothmund M
    Ann Surg; 1998 Jul; 228(1):79-86. PubMed ID: 9671070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
    Mueller J; Gansauge S; Mattfeldt T
    Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
    Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
    Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.
    Sessa F; Solcia E; Capella C; Bonato M; Scarpa A; Zamboni G; Pellegata NS; Ranzani GN; Rickaert F; Klöppel G
    Virchows Arch; 1994; 425(4):357-67. PubMed ID: 7820300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.
    Shibata H; Ohike N; Norose T; Isobe T; Suzuki R; Imai H; Shiokawa A; Aoki T; Murakami M; Mizukami H; Tanaka JI; Takimoto M
    Anticancer Res; 2017 Dec; 37(12):7063-7068. PubMed ID: 29187496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma.
    DiGiuseppe JA; Hruban RH; Offerhaus GJ; Clement MJ; van den Berg FM; Cameron JL; van Mansfeld AD
    Am J Pathol; 1994 May; 144(5):889-95. PubMed ID: 8178941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.
    Z'graggen K; Rivera JA; Compton CC; Pins M; Werner J; Fernández-del Castillo C; Rattner DW; Lewandrowski KB; Rustgi AK; Warshaw AL
    Ann Surg; 1997 Oct; 226(4):491-8; discussion 498-500. PubMed ID: 9351717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in "High-Risk" Lesions.
    Conner JR; Mariño-Enríquez A; Mino-Kenudson M; Garcia E; Pitman MB; Sholl LM; Srivastava A; Doyle LA
    Pancreas; 2017; 46(5):665-671. PubMed ID: 28196015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
    Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
    Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High yields of K-ras mutations in intraductal papillary mucinous tumors and invasive adenocarcinomas induced by N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine in the pancreas of female Syrian hamsters.
    Sugio K; Gazdar AF; Albores-Saavedra J; Kokkinakis DM
    Carcinogenesis; 1996 Feb; 17(2):303-9. PubMed ID: 8625455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
    Morita K; Ono Y; Fukui H; Tomita S; Ueda Y; Terano A; Fujimori T
    Pathol Int; 2000 Mar; 50(3):219-23. PubMed ID: 10792785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
    Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
    Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics of malignant insulinoma.
    Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
    Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colloid (mucinous noncystic) carcinoma of the pancreas.
    Adsay NV; Pierson C; Sarkar F; Abrams J; Weaver D; Conlon KC; Brennan MF; Klimstra DS
    Am J Surg Pathol; 2001 Jan; 25(1):26-42. PubMed ID: 11145249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms: A Multicenter Study.
    Postlewait LM; Ethun CG; McInnis MR; Merchant N; Parikh A; Idrees K; Isom CA; Hawkins W; Fields RC; Strand M; Weber SM; Cho CS; Salem A; Martin RC; Scoggins C; Bentrem D; Kim HJ; Carr J; Ahmad S; Abbott DE; Wilson GC; Kooby DA; Maithel SK
    JAMA Surg; 2017 Jan; 152(1):19-25. PubMed ID: 27760255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.